Does a polypill containing aspirin, ramipril, and atorvastatin reduce major adverse cardiovascular events in patients within 6 months after myocardial infarction?
A polypill strategy containing aspirin, ramipril, and atorvastatin significantly reduces the risk of major adverse cardiovascular events compared to usual care in secondary prevention post-myocardial infarction.
Treatment with a polypill containing aspirin, ramipril, and atorvastatin within 6 months after myocardial infarction resulted in a significantly lower risk of major adverse cardiovascular events than usual care. (Funded by the European Union Horizon 2020; SECURE ClinicalTrials.gov number, NCT02596126; EudraCT number, 2015-002868-17.).
Castellano et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: